Pleiotropic effects of TCF7L2 gene variants and its modulation in the metabolic syndrome: From the LIPGENE study

Atherosclerosis

Volumn 214, Issue 1, 2011, Pages 110-116

  Delgado Lista, J ^a   Perez Martinez, P ^a   Garcia Rios A ^a   Phillips, C M ^b   Williams, C M ^c   Gulseth, H L ^d,i   Helal, O ^e   Blaak, E E ^f   Kiec Wilk, B ^g   Basu, S ^h   Drevon, C A ^d   Defoort, C ^e   Saris, W H ^f   Wybranska, I ^g   Riserus, U ^h   Lovegrove, J A ^c   Roche, H M ^b   Lopez Miranda, J ^a  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

^b UNIVERSITY COLLEGE DUBLIN   (Ireland)

^c UNIVERSITY OF READING   (United Kingdom)

^d UNIVERSITY OF OSLO   (Norway)

^e INSERM   (France)

^f MAASTRICHT UNIVERSITY   (Netherlands)

^g JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^h UPPSALA UNIVERSITY   (Sweden)

ⁱ OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Blood pressure; Insulin resistance; Insulin secretion; LIPGENE; Lipids; Metabolic syndrome; Saturated fatty acids; TCF7L2; Wnt

Indexed keywords

APOLIPOPROTEIN B; CHOLESTEROL; FATTY ACID; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; BLOOD CLOTTING; CARBOHYDRATE METABOLISM; CHOLESTEROL BLOOD LEVEL; DIASTOLIC BLOOD PRESSURE; FAT INTAKE; FATTY ACID BLOOD LEVEL; GENE; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENETIC VARIABILITY; HETEROZYGOTE; HUMAN; INFLAMMATION; INSULIN BLOOD LEVEL; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; METABOLIC SYNDROME X; PHENOTYPE; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE; TCF7L2 GENE;

ADULT; AGED; BLOOD PRESSURE; DIABETES MELLITUS, TYPE 2; FATTY ACIDS; FEMALE; GENETIC VARIATION; HUMANS; INSULIN; INSULIN RESISTANCE; LINKAGE DISEQUILIBRIUM; MALE; METABOLIC SYNDROME X; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; TRANSCRIPTION FACTOR 7-LIKE 2 PROTEIN;

EID: 78650818584     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2010.10.027     Document Type: Article

References (29)

1. Shaw D.I., Hall W.L., Williams C.M. Metabolic syndrome: what is it and what are the implications?. Proc Nutr Soc 2005, 64:349-357.
2. Hickey J.T., Hickey L., Yancy W.S., Hepburn J., Westman E.C. Clinical use of a carbohydrate-restricted diet to treat the dyslipidemia of the metabolic syndrome. Metab Syndr Relat Disord 2003, 1:227-232.
3. Roche H.M., Phillips C., Gibney M.J. The metabolic syndrome: the crossroads of diet and genetics. Proc Nutr Soc 2005, 64:371-377.
4. Florez J.C. Newly identified loci highlight beta cell dysfunction as a key cause of type 2 diabetes: where are the insulin resistance genes?. Diabetologia 2008, 51:1100-1110.
5. Grant S.F., Thorleifsson G., Reynisdottir I., et al. Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes. Nat Genet 2006, 38:320-323.
6. Tabara Y., Osawa H., Kawamoto R., et al. Replication study of candidate genes associated with type 2 diabetes based on genome-wide screening. Diabetes 2009, 58:493-498.
7. Schinner S. Wnt-signalling and the metabolic syndrome. Horm Metab Res 2009, 41:159-163.
8. Florez J.C. The new type 2 diabetes gene TCF7L2. Curr Opin Clin Nutr Metab Care 2007, 10:391-396.
9. Ross S.E., Hemati N., Longo K.A., et al. Inhibition of adipogenesis by Wnt signaling. Science 2000, 289:950-953.
10. Schinner S., Willenberg H.S., Krause D., et al. Adipocyte-derived products induce the transcription of the StAR promoter and stimulate aldosterone and cortisol secretion from adrenocortical cells through the Wnt-signaling pathway. Int J Obes (Lond) 2007, 31:864-870.
11. Tang W., Dodge M., Gundapaneni D., Michnoff C., Roth M., Lum L. A genome-wide RNAi screen for Wnt/beta-catenin pathway components identifies unexpected roles for TCF transcription factors in cancer. Proc Natl Acad Sci U S A 2008, 105:9697-9702.
12. Sousa A.G., Marquezine G.F., Lemos P.A., et al. TCF7L2 polymorphism rs7903146 is associated with coronary artery disease severity and mortality. PLoS One 2009, 4:e7697.
13. Ferguson J.F., Phillips C.M., Tierney A.C., et al. Gene-nutrient interactions in the metabolic syndrome: single nucleotide polymorphisms in ADIPOQ and ADIPOR1 interact with plasma saturated fatty acids to modulate insulin resistance. Am J Clin Nutr 2009, 91:794-801.
14. Perez-Martinez P., Moreno-Conde M., Cruz-Teno C., et al. Dietary fat differentially influences regulatory endothelial function during the postprandial state in patients with metabolic syndrome: from the LIPGENE study. Atherosclerosis 2009, 209:533-538.
15. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001, 285:2486-2497.
16. Shaw D.I., Tierney A.C., McCarthy S., et al. LIPGENE food-exchange model for alteration of dietary fat quantity and quality in free-living participants from eight European countries. Brit J Nutr 2008, 1-10.
17. Matthie J.R. Hydra ECF/ICF Bio-Impedance Analyzer (Mode 4200) Operational Manual Revision 1.01 1997, 44-48. Xitron Technologies Inc., San Diego, CA. X. technologies (Ed.).
18. Gulseth H.L., Gjelstad I.M., Tierney A.C., et al. Serum vitamin D concentration does not predict insulin action or secretion in European subjects with the metabolic syndrome. Diabet Care 2010, 33:923-925.
19. Pilgaard K., Jensen C.B., Schou J.H., et al. The T allele of rs7903146 TCF7L2 is associated with impaired insulinotropic action of incretin hormones, reduced 24h profiles of plasma insulin and glucagon, and increased hepatic glucose production in young healthy men. Diabetologia 2009, 52:1298-1307.
20. Marzi C., Huth C., Kolz M., et al. Variants of the transcription factor 7-like 2 gene (TCF7L2) are strongly associated with type 2 diabetes but not with the metabolic syndrome in the MONICA/KORA surveys. Horm Metab Res 2007, 39:46-52.
21. Camargo A., Azuaje F., Wang H., Zheng H. Permutation-based statistical tests for multiple hypotheses. Source Code Biol Med 2008, 3:15.
22. De Silva N.M., Steele A., Shields B., et al. The transcription factor 7-like 2 (TCF7L2) gene is associated with Type 2 diabetes in UK community-based cases, but the risk allele frequency is reduced compared with UK cases selected for genetic studies. Diabet Med 2007, 24:1067-1072.
23. Florez J.C., Jablonski K.A., Bayley N., et al. TCF7L2 polymorphisms and progression to diabetes in the Diabetes Prevention Program. N Engl J Med 2006, 355:241-250.
24. da Silva Xavier G., Loder M.K., McDonald A., et al. TCF7L2 regulates late events in insulin secretion from pancreatic islet beta-cells. Diabetes 2009, 58:894-905.
25. Rowe J., Corradi N., Malosio M.L., et al. Blockade of membrane transport and disassembly of the Golgi complex by expression of syntaxin 1A in neurosecretion-incompetent cells: prevention by rbSEC1. J Cell Sci 1999, 112(Pt 12):1865-1877.
26. Prokunina-Olsson L., Kaplan L.M., Schadt E.E., Collins F.S. Alternative splicing of TCF7L2 gene in omental and subcutaneous adipose tissue and risk of type 2 diabetes. PLoS One 2009, 4:e7231.
27. Stolerman E.S., Manning A.K., McAteer J.B., et al. TCF7L2 variants are associated with increased proinsulin/insulin ratios but not obesity traits in the Framingham Heart Study. Diabetologia 2009, 52:614-620.
28. Timpson N.J., Lindgren C.M., Weedon M.N., et al. Adiposity-related heterogeneity in patterns of type 2 diabetes susceptibility observed in genome-wide association data. Diabetes 2009, 58:505-510.
29. Chait A., Kim F. Saturated fatty acids and inflammation: who pays the toll?. Arterioscler Thromb Vasc Biol 2010, 30:692-693.